Crystec provide crystal and particle engineering solutions to the pharmaceutical and biopharmaceutical industries through application of the latest modified Supercritical Anti-Solvent (mSAS) technology. We work with clients to help overcome development challenges, and apply the platform to our own assets.
Our services include enhanced polymorph screening, improving stability and generation of scalable co-crystals. The platform is an attractive, single-step alternative to conventional techniques (e.g. micronisation) in terms of process robustness, and ability to control the physical and solid-state properties of the most problematic compounds. mSAS is scaled to commercial cGMP, facilitating a rapid transition from feasibility studies to clinical supply.